INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 18, 2014 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Bona fide gift | 250 | -- | 18,584 |
| Nov 18, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Bona fide gift | 500 | -- | 4,871 |
| Jan 13, 2003 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Bona fide gift | 250 | $19.65 | 15,482 |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 5,149 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 4,800 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 94,851 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 100,000 | -- | -- |
| Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 45,200 | -- | -- |
| Feb 02, 2024 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,750 | $399.66 | 82,769 |
| Feb 02, 2024 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,750 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.